NASDAQ:CSTL
Castle Biosciences Inc.
Castle Biosciences Inc.'s revenue grew 3.7% in fiscal 2025 to $344.2M while operating margin fell to −12.4%. Free cash flow was $28.3M, 8.2% of revenue, and the diluted share count fell 0.9%.Summary generated from Castle Biosciences Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$344.2M
Revenue growth+3.7%
Revenue, 5-yr CAGR+40.6%
Gross margin79.4%
Operating margin−12.4%
Net margin−7.0%
ROIC−9.5%
Return on equity−5.2%
Debt / equity0.02
Free cash flow$28.3M
FCF margin8.2%
Share count change−0.9%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 94 | 137 | 220 | 332 | 344 |
| Operating income | −40 | −73 | −68 | 9 | −43 |
| Net income | −31 | −67 | −57 | 18 | −24 |
| Free cash flow | −22 | −47 | −19 | 37 | 28 |
Recent filings
- 4Insider transaction report
Oct 7, 2026 - 4Insider transaction report
Oct 5, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 30, 2026 - 8-KResults of operations and financial condition
Jul 30, 2026 - 8-KResults of a shareholder vote
May 29, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026 - 8-KResults of operations and financial condition
May 6, 2026 - DEF 14AProxy statement
Apr 8, 2026